Sunshine Biopharma, Inc. (SBFM) — 애널리스트 전망 / 애널리스트 컨센서스 목표가는. 기준 1 애널리스트 평가, 컨센서스는 강세 — 1 매수.
애널리스트 추정 주당순이익(EPS) $-4.12 및 매출 $0.04B 다음 회계연도.
주당순이익(EPS) 실적 추이: 2024: 실적 $-7.32 vs 추정 $-4.12 (하회 -77.7%). 2025: 실적 $-1.44 vs 추정 $-1.01 (하회 -42.6%). 애널리스트 정확도: 63%.
SBFM 애널리스트 등급
Buy
최근 3개월 동안 Sunshine Biopharma, Inc.에 주식 등급을 부여한 1명의 애널리스트 기준
EPS 전망 — SBFM
63%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$7.32
vs Est –$4.12
▼ 43.7% off
2025
Actual –$1.44
vs Est –$1.01
▼ 29.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
매출 전망 — SBFM
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.035B
vs Est $0.038B
▼ 8.4% off
2025
Actual $0.036B
vs Est $0.038B
▼ 3.9% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
